Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States | Zendy

Opeolu Adeoye | Zendy; Richard Hornung | Zendy; Pooja Khatri | Zendy; Dawn Kleindorfer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States

Author(s) -

Opeolu Adeoye,

Richard Hornung,

Pooja Khatri,

Dawn Kleindorfer

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.612358

Subject(s) - medicine , thrombolysis , stroke (engine) , pharmacy , tissue plasminogen activator , fibrinolytic agent , plasminogen activator , ischemic stroke , emergency medicine , t plasminogen activator , diagnosis code , ischemia , family medicine , myocardial infarction , population , mechanical engineering , environmental health , engineering

Recombinant tissue-type plasminogen activator (rtPA) is the only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients in the United States received rtPA. Given incentives from regulatory agencies and payors to increase rtPA use, we hypothesized that rtPA use in the United States would increase from 2005 to 2009.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research